Testing CTIM-76 for recurrent ovarian and other advanced cancers
Part of Cancer, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug, CTIM-76, in people whose ovarian, testicular, or endometrial cancer has come back and is not responding to standard treatments. It aims to see if the drug can shrink tumors or stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be a type that has a specific marker called CLDN6 on its cells.
- You must have ovarian cancer that no longer responds to platinum-based treatments, or advanced testicular or endometrial cancer.
- You must have tumors that can be measured with scans.
- You must be able to take care of yourself (ECOG score 0, 1, or 2) and expected to live at least 12 weeks.
- Your organ function (like liver and kidneys) must be working well enough.
- You cannot have cancer that has spread to the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug for people with advanced solid tumors, especially ovarian, fallopian tube, peritoneal, endometrial, or germ cell cancers that have a specific marker called CLDN6. The goal is to see if the drug is safe and tolerable.
This trial tests a new drug called CTX-10726 in people with advanced kidney, liver, stomach, or uterine cancer that has not responded to standard treatments. The goal is to see if the drug is safe and tolerable.
This trial tests a new cell therapy (GB-5267) for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer. It requires multiple tumor biopsies and aims to see if the treatment can help when standard chemo stops working.
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
This trial tests an experimental drug called IMC-001 for people whose cancer has spread or is locally advanced and has a high number of genetic mutations (TMB-H). The drug aims to help the immune system fight cancer.
This trial tests different doses of a new drug (BI 3820768) in people with advanced solid tumors, specifically germ cell tumors, endometrial cancer, or ovarian cancer. The goal is to see if the drug is safe and how well it works.
Hear when a new Platinum-resistant Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.